Cancer is a generic name for a group of over 200 diseases in which the cells in a part of the body begin to grow in an uncontrolled manner.
Cancer is treated mainly using surgery, radiotherapy, chemotherapy and biological agents. The aim of treatment is to kill the cancer. Unfortunately, however, it can also damage the body’s healthy tissue, which can put great strain on the patient.
At present, no more than around 65 per cent of patients survive for more than five years. For the patients requiring medical treatment the result is even worse. There is, therefore, a great need for new, improved medicinal treatments that specifically attack the cancers.
New findings in areas such as embryology, stem cell research and cell metabolism have today created hopes of more effective methods of treatment in the future, in which the damage to the body’s healthy tissue can largely be avoided.
Kancera AB, with its roots in Pharmacia, Biovitrum and the Karolinska Institute, has two projects which may lead to completely new forms of medicinal treatment, both for solid cancers and for leukaemia. These new forms of treatment aim to attack the internal survival capacity and metabolism of cancers, without damaging the surrounding tissue at the same time.
Kancera AB is now carrying out a new share issue, after which it will be listed on the NASDAQ OMX First North.
My name is Håkan Mellstedt and I am a professor of oncological biotherapy at the Karolinska Institute, and a consultant at the Radiumhemmet Clinic. I have also been Head of the Cancer Centre Karolinska at the Karolinska University Hospital. I am one of the founders of Kancera, and I hope that you, too, will join us and lend your support to this urgent product development.
I would ask you, therefore, to please visit Kancera’s website, www.kancera.com, and read our share issue prospectus, in which our projects are described in detail.
Håkan Mellstedt, Professor of oncological therapy and founder of Kancera AB